IN 2003, the field of cardiac cell signaling celebrates over a decade of achievements detailing the importance of protein kinase C (PKC) family of kinases. Among them, a critical accomplishment has been identification and characterization of extracellular stimuli for PKC isozymes in the heart, including those that are hormonal, neuronal, and mechanical in nature (6, 7, 16) . In particular, tremendous progress has been made in understanding how these stimuli act as upstream triggers to provoke the activation of PKC in cardiac cells (6, 7) . Moreover, considerable evidence supports the concept that PKC functions in an isoform-dependent manner and that the activation of individual isozymes, not the activity of the entire family of kinases, mediates the manifestation of cardiac phenotypes (5, 7, 10, 13) . Therefore, delineation of isozyme-selective downstream targets of PKC, and characterization of molecules that function in accord with PKC activation, will offer mechanistic insight into the pathogenesis of cardiac diseases and aid in the development of novel pharmacological interventions for effective treatment (5, 10, 12, (20) (21) (22) (23) .
Recently, with the establishment of PKC isozymes as essential molecules for the transduction of extracellular signals, increasing effort has been devoted to the downstream signaling events that these kinases orchestrate. A number of investigations have embarked on the search of cellular molecules that are targets of PKC activation (1-4, 7-9, 11-14, 16-22) . Indeed, there are disparities with respect to the molecular makeup of the downstream realm of individual PKC isozymes, which may be due in part to differences in species, cell models, and experimental conditions. Notwithstanding these differences, most studies support the notion that each isoform governs a myriad of downstream signaling events and that activation of an individual isozyme can lead to distinct cardiac phenotypes. In particular, it appears that some of the downstream signaling elements are commonly shared by all isozymes, whereas others are uniquely modulated in an isozyme-specific fashion; nevertheless, all are essential to mediate the biological functions of PKC.
At least two classes of molecular target of PKCs are emerging from these studies. The first contains those that bear consensus domain(s) of unique amino acid sequences that are targets for PKC phosphorylation; thus activation and/or regulation of these molecules involves direct protein-protein interactions between the PKC isozyme and the substrate, and often subsequent posttranslational modification of the substrate by PKC. In contrast to the binding partners depicted in the first class, the second class comprises proteins that are physically distant from PKCs. Accordingly, signaling transduction from PKC to these molecules is usually not associated with PKC phosphorylation-triggered chemical modifications; instead, activation of the second class of molecular targets usually requires ancillary molecules and/or other signaling mediators that themselves are direct substrates of PKCs. Although many myocardial molecules harbor PKC phosphorylation consensus sequences, only a notable few have been shown experimentally to be targets of direct phosphorylation in vivo. Examples include troponin I (4), which impacts contractile function, and the Lck typrosine kinase, which functions as a PKC binding partner in the genesis of cardioprotection against ischemic insults (14) . However, the majority of PKC isozyme-activated molecular targets identified thus far belong to the repertoire of the second class. This rather long list includes MAPKs (2, 3, 6, 11, 17) , the protective kinase Akt (17, 23) , the L-type calcium channel (1), caveolae proteins (15) , and many signaling (2, 3, 6, 8, 11), mitochondrial-associated (8, 9) , and transcription-and translation-related proteins (8, 20) .
It is important to note that the successful development of two key technologies, namely, cardiac-targeted transgenesis and adenovirus-mediated gene transfer, have empowered the investigation of isozyme-selective responses of the PKC family of kinases. These approaches have been critical to the success of these studies in the past decade.
The study by Porter et al., which is the current article in focus (Ref. 15 , see p. C39 in this issue), exemplifies the strategy of adenovirus-mediated gene transfer and elegantly characterizes the effect of PKC isozyme activation on specific downstream signaling events. Using a model that has been previously established to study PKC isozymes and cardiac cell function, they investigated the role of individual PKC isozymes in modulating sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2) gene expression in cardiac cells. Although activation of PKC has been widely documented to induce cardiac hypertrophy in an isoformdependent fashion (7), the manner in which this activation is coupled with diversified downstream signaling events of PKC remains unclear. Thus one of the central questions is to identify and characterize downstream targets of PKC isoforms that facilitate their isoform-specific action. The authors approached this question by examining whether there is a distinct effect of individual PKC isoforms on the expression of SERCA2; their results offer new insights regarding mechanisms of PKC signaling as well as the biology of cardiac hypertrophy.
Two important, novel findings in this study are: 1) activation of PKC⑀ and PKC␦, at levels that did not impact cardiac cell size, was shown to significantly downregulate SERCA2 gene expression; and 2) activation of PKC␣, at levels that have been previously documented to induce cardiac cell hypertrophy, did not trigger altered SERCA2 gene expression. Together, these data indicate that PKC isoforms may target distinct downstream signaling events, as illustrated by their regulation of SERCA2 gene expression.
As we move forward in our search for isozyme-selective molecular targets of PKC, we are presented with new challenges. There is increasing consensus that the activation of molecular targets of PKC is profoundly influenced by at least three fundamental factors: location (i.e., the subcellular compartment at which the isozyme resides), time (i.e., the temporal profile that the isozyme displays), and quantity (the amplitude of expression that the isozyme exhibits). Success in addressing those issues will require experimental strategies that are effective in defining the cellular location where a particular PKC isozyme is expressed and activated, will necessitate approaches that tightly regulate the temporal expression of PKC isozymes, and will demand methodologies that are capable of monitoring the level of expression with a greater degree of precision. The rapid development of several technologies, such as conditional and tissue-specific transgenesis and the use of organelle-targeting sequences to enable subcellular compartment specific expression, will aid our efforts in this direction. It may take considerable time before complete success in such efforts is achieved; nevertheless, the outcomes are likely to be extraordinary, especially in terms of precisely defining isozyme-selective molecular targets in a subcellular compartment-, time-, and quantity-specific fashion. These lines of information will enable the construction of cellular maps portraying all molecular substrates and downstream targets of PKC in an isozyme-specific manner, thus providing a holistic view of PKC signaling subproteomes.
